VIP方案治疗对68例晚期非小细胞肺癌疗效观察  

A clinical study on VIP in treatment of 68 patients with advanced non-small cell lung cancer

作　　者：杨和平[1] 戴晓天[1] 刘刚[1] 熊玮[1] 

机构地区：[1]第三军医大学西南医院呼吸科,重庆400038

出　　处：《重庆医学》2002年第9期772-773,共2页Chongqing medicine

摘　　要：目的　VIP方案治疗晚期非小细胞肺癌 (NSCLC)的近期疗效及毒副反应的观察。方法　 6 8例晚期非小细胞肺癌患者给予异环磷酰胺 (IFO) 1.2～ 2 .0 /m2 d1～ 5静滴 ;DDP 2 5mg/m2 d1～ 4静滴 ;Vpl6 10 0mgdl～ 5静滴。巯基乙磺酸钠 (美司钠mesna) 4 0 0mg ,静点IFO同时、之后 4h、8h分别静冲。每 3周重复疗程。结果　VIP方案治疗非小细胞肺癌总有效率 4 7.1% ,其中CR3例 (4.4 % ) ,PR2 9例 (42 .6 % ) ,SD32例 (47.1% ) ,PD4例 (5 .8% )。 4 2例初治者和 2 6例复治者近期有效率分别为 5 4 .8%、38.5 % ,中位生存期 9.6个月 (6～ 18个月 ) ,1年生存率为 35 .6 %。主要毒副反应为中度骨髓抑制和胃肠道反应。Objective To evaluate the efficacy and toxicity of VIP(ifosfamide,cisplatin and etoposide) in treatment of patients with advanced non small cell lung cancer(NSCLC). Methods Sixty eight patients with locally advanced (stage III) or metastatic (stage IV) NSCLC were enrolled into the study. The patients received ifosfamide 1.2～2.0g/m 2 by 3 hours iv infusion on days 1～5, mesna 400mg by iv bolus at hours 0, 4, and 8 on days 1～5 , cisplatin 25mg/m2 by 2 hours iv infusion on day1～4 and etoposide 100mg by 2 hour iv infusion on days 1～5. Courses were repeated every 3 weeks. Results The over all response rate was 47.1% with 3(4.4%) CR and 29(42.6%) PR. The disease was stable in 32 patients(47.1%) and was progressive in 4 patients(5.8%). The response rate was 54.8% in patients with no prior chemotherapy, and 38.5% in patients who had given prior treatment. No significant difference existed between the two groups ( P >0.05). The median duration of survival was 9.6 months, and 1 year survival rate was 35.6%. Toxicity was chiefly hematologic in the form of neutropenia. The major nonhematologic toxicity was nausea or vomiting. Conclusion The VIP combination chemotherapy is an active regimen for advanced NSCLC with tolerable toxicity.

关 键 词：VIP方案 治疗 晚期非小细胞肺癌 疗效观察 药物疗法 

分 类 号：R734.2[医药卫生—肿瘤] R730.53[医药卫生—临床医学]